ABC | Volume 113, Nº1, Julho 2019

Posicionamento Posicionamento sobre Indicações da Ecocardiografia em Adultos – 2019 Arq Bras Cardiol. 2019; 113(1):135-181 echocardiography for noninvasive assessment of cardiac allograft vasculopathy:a comparison with coronary angiography and intravascular ultrasound. Circulation. 1999;100(5):509-15. 55. Sade LE, Eroglu S, Yuce D, Bircan A, Pirat B, Sezgin A, et al. Follow-up of heart transplant recipients with serial echocardiographic coronary flow reserve and dobutamine stress echocardiography to detect cardiac allograft vasculopathy. J Am Soc Echocardiogr. 2014;27(5):531-9. 56. Hacker M, Hoyer HX, Uebleis C, Ueberfuhr P, Foerster S, La Fougere C, et al. Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echocardiography:a comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT. Eur J Echocardiogr. 2008;9(4):494-500. 57. Rutz T, de Marchi SF, Roelli P, Gloekler S, Traupe T, Steck H, et al. Quantitative myocardial contrast echocardiography:a new method for the non-invasive detection of chronic heart transplant rejection. Eur Heart J Cardiovasc Imaging. 2013;14(12):1187-94. 58. Tona F, Caforio AL, Montisci R, Gambino A, Angelini A, Ruscazio M, et al. Coronary flow velocity pattern and coronary flow reserve by contrast- enhanced transthoracic echocardiography predict long-termoutcome in heart transplantation. Circulation. 2006;114( 1 Suppl):I49-55. 59. Tona F, Osto E, Tarantini G, GambinoA, Cavallin F, FeltrinG, et al. Coronary flow reserve by transthoracic echocardiography predicts epicardial intimal thickening in cardiac allograft vasculopathy. Am J Transplant. 2010;10(7):1668-76. 60. Miller LW, Labovitz AJ, McBride LA, Pennington DG, Kanter K. Echocardiography-guided endomyocardial biopsy. A 5-year experience. Circulation. 1988;78(5 Pt 2):III99-102. 61. DaherIN,DaigleTR,BhatiaNandDurandJB.Thepreventionofcardiovascular disease in cancer survivors. TexHeart Inst J. 2012;39(2):190-8. 62. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer:cardio-oncology. Mayo Clin Proc. 2014;89(9):1287-306. 63. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy:a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-93. 64. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy:comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876-84. 65. Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol. 2013;61(1):85-7. 66. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy:clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20. 67. Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, et al. Normal range of left ventricular 2-dimensional strain:JapaneseUltrasound Speckle TrackingoftheLeftVentricle (JUSTICE)study.Circ J.2012;76(11):2623-32. 68. Pudil R, Horacek JM, Strasova A, Jebavy L, Vojacek J. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol. 2008;30(2):160-2. 69. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-54. 70. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. 71. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy:ESMOClinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155-66. 72. Elliott PM, Anastasakis A, Borger MA, BorggrefeM, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. 73. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J AmColl Cardiol. 2009;54(3):220-8. 74. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. 75. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212-60. 76. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(12):1727-31. 77. Urbano-MoralJA,RowinEJ,MaronMS,CreanA,PandianNG.Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7(1):11-9. 78. Bharucha T, Lee KJ, Daubeney PE, Nugent AW, Turner C, Sholler GF, et al. Sudden death in childhood cardiomyopathy:results from a long-term nationalpopulation-basedstudy. JAmCollCardiol.2015;65(21):2302-10. 79. Risgaard B, Winkel BG, Jabbari R, Behr ER, Ingemann-Hansen O, Thomsen JL, et al. Burden of sudden cardiac death in persons aged 1 to 49 years:nationwide study in Denmark. Circ Arrhythm Electrophysiol. 2014;7(2):205-11. 80. Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, et al. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults AssociatedWith LowCardiovascularMortalityWithContemporary Management Strategies. Circulation. 2016;133(1):62-73. 81. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies:a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-6. 82. Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. Eur J Echocardiogr. 2009;10(8):iii23-33. 83. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):819-37. 84. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis fromother causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411-5. 85. Murtagh G, Laffin LJ, Patel KV, Patel AV, BonhamCA, Yu Z, et al. Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography. 2016;33(9):1344-52. 86. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy:an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175-87. 175